Actively Recruiting
Study of the Link Between MASH ( Metabolic Dysfunction-Associated Steatohepatitis) and MAMs (Mitochondria-Associated Membranes ) Alteration in Patients Undergoing Bariatric Surgery - MAMBA
Led by Hospices Civils de Lyon · Updated on 2026-01-15
20
Participants Needed
2
Research Sites
150 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main research hypothesis is that alterations in the communication between the endoplasmic reticulum (ER) and the mitochondria at contact sites called mitochondria-associated membranes (MAMs) occurs in different hepatic cell types of patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MALSD) and is involved in the progression towards MASH and could also influence the process of improvement of MASH. This study aims to investigate the link between Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Mitochondria-Associated Membranes (MAMs) in liver cells and peripheral blood mononuclear cells (PBMCs) in patients undergoing bariatric surgery. The primary objective is to analyze MAMs alterations in hepatocytes in MASH patients compared to non-MASH patients. Secondary objectives include evaluating the correlation between MAMs in PBMCs and liver cells and assessing MAMs changes post-bariatric surgery.
CONDITIONS
Official Title
Study of the Link Between MASH ( Metabolic Dysfunction-Associated Steatohepatitis) and MAMs (Mitochondria-Associated Membranes ) Alteration in Patients Undergoing Bariatric Surgery - MAMBA
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female or male adult patients
- Patients approved for sleeve gastrectomy or gastric bypass after multidisciplinary evaluation
- Patients with indication for intraoperative liver biopsy due to suspected MASH
- Patients who agree to participate and sign informed consent
- Patients affiliated with a healthcare insurance plan
You will not qualify if you...
- Patients with hepatitis B or presence of hepatitis B surface antigen
- Patients with previous or current hepatitis C infection
- Patients with autoimmune hepatitis or autoimmune cholestatic liver disorders
- Patients with Wilson disease or Alpha-1-antitrypsin deficiency
- Patients with Hemochromatosis
- Patients with drug-induced liver disease
- Patients with bile duct obstruction
- History of taking medications causing steatosis in the last 6 months
- Evidence or history of liver cirrhosis or portal hypertension
- Regular or excessive alcohol consumption over past 10 years
- History of HIV infection
- History of type 1 diabetes
- Pregnant or breastfeeding women
- Minors
- Patients deprived of liberty or under psychiatric care
- Patients admitted for non-research health or social care
- Mentally unbalanced patients or under guardianship
- Patients not affiliated with social security or similar
- Patients unable to understand French or give consent
- Patients already enrolled in interfering trials
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Hospices Civils de Lyon - Hôpital Edouard Herriot
Lyon, France, France, 69003
Actively Recruiting
2
Centre Hospitalier Lyon Sud, Endocrinologie, Diabète et nutrition
Pierre-Bénite, France, France, 69495
Actively Recruiting
Research Team
C
Cyrielle CAUSSY, Pr
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here